Abstract | BACKGROUND: AIMS: The aim of this study isto describe the tolerance and efficacy of compassionate use of ponatinib in a paediatric cohort of patients with Ph+ leukaemias. METHODS: Data from 11 children with chronic myeloid leukaemia (CML) registered to the international registry of childhood chronic myeloid leukaemia and from 3 children with Ph+ acute lymphoblastic leukaemia (Ph+ ALL) treated with ponatinib were collected retrospectively. RESULTS: In 11 girls and 3 boys (median age 14 years), ponatinib was used as a second- to eighth-line treatment. Ponatinib was administered as single therapy (9 patients) or in combination with chemotherapy (8 patients). The status of the disease when ponatinib was started was as follows: CML in advanced phases (n = 8), CML in chronic phase without achievement of molecular response (n = 2) or presence of T315I mutation (n = 1) and Ph + ALL in molecular (n = 1) or marrow (n = 2) relapses. The median dose administered was 21.4 mg/m2 and median duration of ponatinib was 2.5 months. Ponatinib alone or in combination with chemotherapy administered on 16 occasions led to achievement of major molecular response in 50% of cases. Ponatinib was used as a bridge to transplant in 4 cases. Among the 9 patients treated with ponatinib alone, toxicity grade III-IV (2 patients) was exclusively haematologic. No vascular events related to ponatinib were observed. CONCLUSION:
Ponatinib may be a reasonable additional treatment option for children with Ph+ leukaemias who have failed several lines of therapy.
|
Authors | Frédéric Millot, Meinolf Suttorp, Anne B Versluys, Krzysztof Kalwak, Brigitte Nelken, Stephane Ducassou, Yves Bertrand, André Baruchel |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 136
Pg. 107-112
(09 2020)
ISSN: 1879-0852 [Electronic] England |
PMID | 32668374
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier Ltd. All rights reserved. |
Chemical References |
- Imidazoles
- Pyridazines
- ponatinib
- Fusion Proteins, bcr-abl
|
Topics |
- Adolescent
- Age of Onset
- Child
- Child, Preschool
- Female
- Fusion Proteins, bcr-abl
(genetics)
- Humans
- Imidazoles
(therapeutic use)
- International Cooperation
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, epidemiology, genetics, pathology)
- Male
- Philadelphia Chromosome
- Pyridazines
(therapeutic use)
- Registries
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
|